Browsing Tag
Jon Pilcher
2 posts
Neuren Pharmaceuticals (ASX: NEU) gains fourth US orphan drug designation for NNZ-2591
Neuren Pharmaceuticals has received United States orphan drug designation for NNZ-2591 in neonatal hypoxic-ischaemic encephalopathy, expanding regulatory incentives for its neurological drug pipeline while a required juvenile animal safety study delays the proposed clinical development programme.
Neuren Pharmaceuticals advances NNZ-2591 for Phelan-McDermid syndrome to Phase 3 clinical trial
Neuren Pharmaceuticals has secured approval from the United States Food and Drug Administration (FDA) to progress into the…